EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSBGRG00000001064
Gene Symbol: ATP1B3
1 Cross references
291 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSBGRG00000000428
Gene Symbol: ATR
1 Cross references
207 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSBGRG00000020110
Gene Symbol: AXL
1 Cross references
198 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBGRG00000000301
Gene Symbol: BRAF
1 Cross references
220 Possible Orthologues:

Bcl2 Like 2

Ensembl ID : ENSBGRG00000006983
Gene Symbol: BCL2L2
1 Cross references
64 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSBGRG00000023669
Gene Symbol: BCR
1 Cross references
286 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSBGRG00000019910
Gene Symbol: BTK
1 Cross references
207 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSBGRG00000010345
Gene Symbol: CCR2
1 Cross references
150 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSBGRG00000022769
Gene Symbol: CCR4
1 Cross references
113 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSBGRG00000010403
Gene Symbol: CCR5
1 Cross references
152 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSBGRG00000009789
Gene Symbol: CCR9
1 Cross references
265 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSBGRG00000020347
Gene Symbol: CXCL8
1 Cross references
179 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).